Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis
关键词
抽象
描述
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease. The course of the disease is characterized by a slow destruction of bile ducts, and progressive cholestasis. Prognosis depends on the development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) has been established as standard therapy for PBC and improves patients' long-term outcome. However, UDCA is not a uniformly effective drug, and the prognosis of PBC patients insufficiently responding to treatment is markedly worse. For patients with suboptimal treatment response to UDCA obeticholic acid (OCA) as newly approved medication (OCALIVA®) is available as second line treatment.
Due to the low prevalence and the slowly progressive course of the disease it is very difficult to investigate the prognosis of subgroups of PBC patients or to evaluate the effectivness of therapeutic interventions on clinical outcomes. Therefore, several national or international registries (UK-PBC Consortium or the Global PBC Study Group) were founded to better characterize the clinical course of PBC patients.
Since in Germany a registry for PBC does not exist, the German PBC Cohort is being implemented as observational study to collect data on treatment progress and success in clinical routine that reflects real world conditions in Germany as closely as possible. The effectiveness and safety/tolerability of PBC treatment options (UDCA as standard therapy and second-line treatment options like OCALIVA in case of inadequate UDCA treatment response) will be evaluated.
In approximatly 40 sites in Germany routine data is collected. There are no specifications for the diagnosis, therapy and monitoring of the PBC patients. The documentation of the routine data is carried out alongside with guideline recommended treatment intervals of the patients.
Furthermore, a critical criterion for the German PBC Cohort study is the involvement of a sufficient number of gastroenterology specialized practices and outpatient clinics that have consciously not been selected based on the strict specifications of a clinical trial and which provide routine treatment for PBC patients. In addition, patient access is designed to be open. Data will be collected on patient groups that represent a majority of the PBC patients in Germany, but who are not being investigated in clinical trials.
日期
| 最后验证: | 07/31/2019 |
| 首次提交: | 08/28/2019 |
| 提交的预估入学人数: | 08/28/2019 |
| 首次发布: | 09/02/2019 |
| 上次提交的更新: | 08/28/2019 |
| 最近更新发布: | 09/02/2019 |
| 实际学习开始日期: | 08/31/2019 |
| 预计主要完成日期: | 02/29/2024 |
| 预计完成日期: | 02/29/2024 |
状况或疾病
干预/治疗
Drug: UDCA
Drug: Ocaliva
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Group 1 - Incomplete Responder Primary Incomplete Responder: PBC patients demonstrating an insufficient response to the standard therapy with ursodeoxycholic acid (UDCA) after a minimum of 12 months of treatment (Paris II criteria).
Secondary Incomplete Responder: PBC patients demonstrating a satisfactory initial response to UDCA after a minimum of 12 months of treatment (Paris II criteria) followed by a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment. | |
| Group 2 - Responder PBC patients demonstrating a satisfactory initial and contin-ued response to UDCA after a minimum of 12 months of treatment (Paris II criteria) without a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment. | |
| Group 3 Patients newly diagnosed for PBC receiving an approved PBC therapy for the first time. Patients are considered to be newly diagnosed if the initial diagnosis took place no later than six months prior to inclusion into the study. |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 取样方式 | Non-Probability Sample |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: 1. Age ≥ 18 years 2. Diagnosis of PBC PBC diagnosis (consistent with AASLD and EASL practice guidelines), as demonstrated by the presence of at least two of the following three diagnostic factors: - History of elevated ALP levels for 6 months. - Positive anti-mitochondrial antibody (AMA) titer or if AMA negative or in low titer (<1:80) => PBC-specific antibodies: - anti-GP210 and/or - anti-SP100 and/or - antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex (OADC-E2), branched-chain-2-oxo-acid-dehydrogenase complex, (BCOADC-E2)]. - Liver biopsy consistent with PBC. 3. Medication-based treatment with at least one drug approved in Germany for the treatment of PBC 4. Availability of all following essential parameters at the initial diagnosis of PBC prior to the initiation of treatment with UDCA, 12 months after initiation of UDCA and if applicable at time point of secondary incomplete response: - Platelet count - Alkaline Phosphatase (ALP) - Total Bilirubin - Aspartate aminotransferase (AST/GOT) - Age at initial diagnosis of PBC 5. Patients must meet criteria of one of the cohorts (group 1/2/3) within this NIS according to design 6. written statement of informed consent Exclusion Criteria: Current participation in a phase I to IV interventional clinical trial for PBC or participation in another PBC registry. |
结果
主要结果指标
1. Systematic registry [from baseline to 36 months after baseline (observational period)]
次要成果指标
1. Comprehensive clinical characterization of German PBC patients [from baseline to 36 months after baseline]
2. Characterization of PBC therapies [from baseline to 36 months after baseline]
3. Treatment response to PBC therapies after 12 months and during longer courses of application [from baseline to 12 months after baseline and to 36 months after baseline]
4. Application and analyses of existing prognostic PBC scores to provide information on patients' prognosis. [from baseline to 36 months after baseline]
5. Concomitant Medications [from baseline to 36 months after baseline]
6. Concomitant Autoimmune Diseases [from baseline to 36 months after baseline]
7. Concomitant Non-Autoimmune Diseases [from baseline to 36 months after baseline]
